Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Accounts Payables: 2018-2025

Historic Accounts Payables for Whitehawk Therapeutics (WHWK) over the last 8 years, with Sep 2025 value amounting to $1.6 million.

  • Whitehawk Therapeutics' Accounts Payables rose 18.85% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 18.85%. This contributed to the annual value of $2.2 million for FY2024, which is 63.39% down from last year.
  • Whitehawk Therapeutics' Accounts Payables amounted to $1.6 million in Q3 2025, which was down 51.09% from $3.3 million recorded in Q2 2025.
  • Over the past 5 years, Whitehawk Therapeutics' Accounts Payables peaked at $6.5 million during Q1 2023, and registered a low of $1.4 million during Q3 2024.
  • In the last 3 years, Whitehawk Therapeutics' Accounts Payables had a median value of $2.9 million in 2023 and averaged $3.2 million.
  • In the last 5 years, Whitehawk Therapeutics' Accounts Payables skyrocketed by 169.19% in 2021 and then crashed by 63.39% in 2024.
  • Quarterly analysis of 5 years shows Whitehawk Therapeutics' Accounts Payables stood at $6.4 million in 2021, then plummeted by 45.35% to $3.5 million in 2022, then soared by 67.60% to $5.9 million in 2023, then crashed by 63.39% to $2.2 million in 2024, then grew by 18.85% to $1.6 million in 2025.
  • Its Accounts Payables was $1.6 million in Q3 2025, compared to $3.3 million in Q2 2025 and $3.7 million in Q1 2025.